As Longevity Investors Conference gets underway, David Sinclair reflects on advancements in longevity research and the need for translation.
Having kicked off yesterday with networking and socializing, the Longevity Investors Conference gets into the full swing of its program over today and tomorrow. Set against the scenic backdrop of Gstaad, the Conference attracts a unique blend of investors, innovators and scientists, all with a shared vision of harnessing cutting-edge biotechnology to slow or even reverse the effects of aging.
Longevity.Technology: One of those scientists is David Sinclair, a key figure in the longevity world, who will speak on the Future of Longevity Interventions on Thursday. Known for his instrumental research into the biology of aging, Sinclair’s insights have advanced our understanding of the aging process, helping to spark the global interest in longevity science. His work has focused on advancing potential therapies aimed at extending human lifespan and improving healthspan, making him a pioneer in the space.
Sinclair’s session on Thursday is highly anticipated, but we managed to grab some time with him to discuss his latest research, the conference and more.
Geroscience is a fast-moving field with new papers published and new discoveries made all the time. Sinclair keeps his ear to the ground, and can often be seen sharing interesting research on X, and he tells us there are myriad new and exciting developments in the longevity field.
“I am particularly looking forward to the intersection of AI and longevity with the ability to monitor biomarkers, diagnose diseases, and find new medicines faster than ever,” he says.
Sinclair, who is Professor in the Department of Genetics at Harvard Medical School, explains that the introduction of AI and robotics in the lab is set to transform most areas of research.
“I think if we can understand how it is possible for a cell to rejuvenate itself – if and where that information is stored – that holds the possibility of changing how we view and treat aging and age-related diseases,” Sinclair says. “I remain positive about progress in killing and curing senescent cells, finding new longevity pathways, unifying the hallmarks of aging, and coming to consensus about the biomarkers of aging with the possibility of them being used not only in research but in standard medical practice.
And of course, Dr Sinclair is excited about the new developments in his lab, as he and his team continue to find new ways to “reprogram tissues to be younger” using gene therapy and chemical cocktails.
“Next year, the first person will be reprogrammed by Life Biosciences using our lab’s technology and, if all goes well, vision will be improved in those patients,” he said. “This could be the beginning of numerous potential reprogramming therapies to be tested in the clinic to treat age-related diseases.”
While longevity research is accelerating, in order for there to be real progress, discoveries have to be translated into practical interventions – and for many, the pace isn’t moving as fast as it should.
“Currently, progress is too slow,” agrees Sinclair, who says he is hopeful that AI can increase discovery and the progress and success of drug development “by at least an order of magnitude”.
“Increased funding of basic research is also important to allow scientists to find new and cheaper ways to delay and reverse aging,” he adds.
The Longevity Investors Conference has a diverse lineup of speakers and attendees and fosters partnerships through numerous networking and break-out sessions, and Sinclair notes the importance of events such as these, making the point that while collaboration between scientists has been essential to progress over the last century, he feels that the situation has deteriorated.
“Sadly, over the last decade, we have seen a decline in the ability of US scientists to collaborate globally due to increased restrictions and scrutiny, borne largely from a concern at the federal level about loss of intellectual property,” he explains. My hope is a compromise can be reached that will protect intellectual property while allowing for greater collaboration between scientists.”
And Sinclair is looking forward to Longevity Investors Conference, of course!
“I’m particularly interested in hearing the advancements in longevity science, the effects of drug combinations, and the latest advancements in drug development,” he says.
CLICK HERE to find out more about Longevity Investors Conference
